04 September 2016
A report by visiongain, published in August 2016, predicts the world pre-filled injection devices market will generate $6940m in 2020, with rapid sales expansion to 2026. That forecast and others appear in Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2016-2026 – Profiles, R&D and Revenue Forecasting for Leading Syringe, Injector and Component Producers and Contract Manufacturers (CMOs) Including BD, Gerresheimer, Aptar Stelmi, Dätwyler, Ypsomed, Catalent and Vetter; Analysis of Products Including Glass and Plastic Syringes, Cartridges, Pen Injectors, Autoinjectors, Safety Systems and Accessories; Assessment of Companies Specialising in Ready-to-Fill Drug Delivery Systems for Vaccines, Insulin and Biological Drugs, Including Clinic- and Home-Based Applications.
That investigation predicts revenues and trends for the overall pre-filled injection devices market. It also shows discussions, analyses, prospects, R&D and revenue forecasts for leading specialists in the US, Europe, and Asia. Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help companies and other organisations assess the potentials of industries and market in healthcare and other fields.
The report’s author notes: “Companies in the pre-filled injection devices market will benefit from the main long-term drivers of growth in the pharmaceutical market which will generate in this market. As life expectancy increases and the ageing population increases, there will be a global rise in demand for healthcare pre-filled medical devices. For example, the number of diabetes patients will increase worldwide, leading to a rise in demand for insulin pens, and this trend will be across many disease populations that can benefit from pre-filled medical devices. The global cancer population will increase along with other disease and innovative drugs will be in demand, which will also create a need for manufacturing novel packaging and drug delivery systems that will protect the new treatments. However, this market has high barriers of entry such as the required expertise, and companies that wish to enter this market should aim to take advantage of the shift towards biologics and novel medicines that will need innovative delivery systems."
Visiongain’s updated study covers pre-filled injection device manufacturers from the following four sectors of the industry – pre-filled syringe manufacturers, component manufacturers, pen injector and autoinjector manufacturers, and contract manufacturing organisations (CMOs) providing filling services for pre-filled injection devices (syringes and cartridges).
That new report analyses 25 leading pre-filled injection device manufacturing companies in the US, Europe and Asia. It explores firms’ activities by:
• Analysing pre-filled injection device product portfolios and technologies
• Investigating the status of developmental products, assessing R&D, progress and possibilities
• Providing revenue forecasts for 10 leading companies from 2016 to 2026
• Giving qualitative analyses (SWOT) of leading companies in that industry and market.
• Interviewing an authority in the field, revealing insights on that technology and its future
• Showing qualitative analyses (STEP) of that industry and market.
A selection of the 25 organisations visiongain covers follow. Companies the survey assesses include these leading pre-filled injection device manufacturers:
• Becton, Dickinson, & Co (BD)
Profiles for leading component manufacturers also appear, including these companies:
• Aptar Stelmi
• Dätwyler Holding
• West Pharmaceutical Services.
Discussions of leading pen injector and autoinjector manufacturers also appear, including these firms:
• Owen Mumford
• SHL Group
Profiles of leading contract manufacturing organisations (CMOs) offering pre-filled syringe filling services appear too, including these service providers:
• Hospira One2One
• Vetter Pharma.
Medical Device Leader Series: Top Pre-Filled Injection Device Manufacturers 2016-2026 analyses organisations well placed to contribute to and benefit from the expected commercial expansion from 2016 to 2026. That investigation adds to visiongain’s reports on industries and markets in healthcare, including studies on pharmaceuticals, biotechnology, medical devices, diagnostics and outsourced services. Each year more new and updated studies appear.
The market for ophthalmic drugs is a growing one.
17 June 2019
Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.
14 June 2019
The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.
06 June 2019
Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.